In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward?

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

The Population Council’s microbicide work is supported by the United States Agency for International Development (USAID) Cooperative Agreement GPO-A-00-04-00019-00, the Swedish Ministry for Foreign Affairs, the Swedish International Development Cooperation Agency, the NIH base grant RR00164, and with federal funds from the National Cancer Institute, NIH, under contract HHSN2612008000001E. The contents of this manuscript are the sole responsibility of the Population Council and do not necessarily reflect the views or policies of USAID or the US government. The funders had no role in study design, data collection and analysis, or decision to publish data mentioned in this manuscript nor did they participate in preparation of this manuscript or others reporting data mentioned herein. M Robbiani is a 2002 Elizabeth Glaser Scientist. The authors declare that they have no competing interest. Patents pertaining to the compound MIV-150 and related methods for making the same are exclusively licensed to The Population Council Inc. by Medivir AB and cannot be given to any outside group without a Material Transfer Agreement (MTA). The Population Council will consider reasonable requests for access to MIV-150 for research purposes, which, if granted, will require establishment of an MTA.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.